FDA trial overhaul: faster approvals, overdue safety studies
A new HHS project wants to speed clinical trials while the FDA leans on postmarket studies that are often late. Drugmakers are already moving billions into the pipeline.
The United States is trying to shorten the road between a laboratory discovery and a pharmacy shelf.
Health Secretary Robert F. Kennedy, Jr. and ARPA-H Director Alicia Jackson launched a project in Austin, Texas, to accelerate the clinical trial process. The experimental program, reported by Axios, aims to reduce the total amount of time and money required to conduct medical trials. Axios frames the effort as one that could reconfigure the drug development process and increase U.S. competitiveness in the global biotechnology market.
The front-end ambition is running into an older problem at the back end. The FDA is allowing companies to conduct required safety and efficacy studies after their drugs and devices have already reached the market, and agency records show many of those postmarket studies are currently overdue or behind schedule, the Inquirer reports. The same reporting notes that a shift toward requiring only one clinical trial instead of two for approval increases the reliance on those delayed post-approval studies to ensure patient safety. NewzBits covered the backlog here.
Read together, the two moves describe a pipeline that may be asked to move faster while the verification work that follows approval is still catching up.
Where the money is already pointed
Sanofi agreed to pay Regeneron $1 billion upfront and up to $7 billion in milestone payments to co-develop four drugs, per a Reuters health summary. The two companies will split all development costs and future profits equally, with Sanofi managing global sales upon approval. The partnership allows Regeneron to leverage Sanofi's commercial infrastructure to bring new pharmaceutical treatments to market. Full item.
Tag
mindfulness
Condividi
For a smaller developer, the milestone looks different. NanoViricides filed its annual report, Form 10-K for the fiscal year ending June 30, 2026, with the Securities and Exchange Commission on September 28, 2026. The company is conducting Phase II clinical trials for NV-387, a broad-spectrum antiviral designed to treat difficult viral infections. The drug aims to fill a critical gap in medical countermeasures: there is currently no approved drug for the treatment of MPox Clade I or Clade II, Yahoo Finance notes.
The patients trials tend to miss
Faster trials do not automatically mean broader access, and early-October health equity reporting shows where the gaps sit. Lung cancer screening rates for people with HIV remain low even after eligibility for the tests tripled, according to AJMC's weekly roundup. The roundup suggests patients may face better outcomes if clinics implement embedded prompts and reminders, and if trials adopt decentralized designs that reduce the number of required visits. It also notes that policy-mandated coverage for housing and caregiver support could increase inclusivity and access for transplant patients. Read the roundup.
Those findings brush against the trial redesign conversation. The mechanics of a study, from how many visits it requires to who gets a reminder to come back, shape who can take part at all.
Information is another form of access, and the National Institutes of Health is addressing its own version of the problem. The agency is launching a streamlined website to help the public find health and research information more easily. One communications expert described the redesign as badly needed, telling Statnews that finding information on the old site required the skills of an Egyptologist. The update removes the requirement for users to understand the complex internal organizational structure of the agency to navigate the site. Details here.
What the pipeline is up against
The World Health Organization released new Global Health Estimates on 2 October 2026, detailing health trends across countries and regions from 2000 to 2023. Global life expectancy has returned to levels close to those seen before the COVID-19 pandemic. Noncommunicable diseases, including diabetes, dementia, and mental health conditions, now account for an increasing share of global deaths, the agency says. NewzBits summary here. The estimates describe the landscape in which the U.S. changes are landing.
Infectious threats remain part of that landscape. The Pan American Health Organization held a briefing session on October 1, 2026, in Washington, D.C., to discuss accelerating the elimination of communicable diseases in the Americas. The session focused on using national leadership and strategic investments to eliminate more than 30 communicable diseases and related health conditions, PAHO/WHO said, with increased funding and partnerships between health authorities and international organizations required to remove those public health threats from the region. More here.
Meanwhile, a Reuters summary carried a different kind of warning: thousands of people have fled an Ebola-hit camp in Congo, increasing the risk of the disease spreading to other areas.
The gap behind the finish line
Approval is not the end of the evidence trail. The FDA's postmarket studies are supposed to close it, and many are behind schedule. The HHS project in Austin is aimed at the months and dollars that come before approval. The Sanofi-Regeneron deal shows how much commercial conviction rests on the other end of that sequence: four drugs, split costs, split profits, and a sales organization waiting on approval.
The health equity reporting adds a narrower question. If trials become faster but not more reachable, the people already missing from screening and transplant lists may stay missing from the studies that decide what treatments look like.
None of these items settles the other. A trial accelerator, a backlog of overdue studies, a multibillion-dollar partnership, a Phase II antiviral, and fresh estimates of who dies from what are separate facts pointing at one system. The test of the Austin experiment is whether it shortens the front end without stretching the back.